Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042665 · ClinicalTrials.gov registry record
Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo
A clinical trial, sponsored by University of Miami.
- Completed
- Registry status
- 82
- Enrollment target
NCT01042665 is a clinical trial that has completed, run by University of Miami. The registered enrollment target is 82 participants.
The verdict
NCT01042665 has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.
Interventions
- DRUG Placebo
- DRUG latanoprost 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042665
The ClinicalTrials.gov registry entry for NCT01042665 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042665 about?
NCT01042665 is a clinical study titled "Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo". The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.
What is the current status of trial NCT01042665?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2006-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01042665?
The interventions under investigation include: Placebo (DRUG), latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT01042665?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.